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Background: Given the complexity of tumor microenvironment, no single marker from cancer cells could
adequately predict the clinical outcomes of gastric cancer (GC). The objective of this study was to evaluate the
prognostic role of combined features including conventional pathology, proteinase and immune data in GC.
Methods: In addition to pathological studies, immunohistochemistry was used to assess membrane-type 1 matrix
metalloproteinase (MT1-MMP) expression and CD11b + immunocytes density in three independent GC tissue
microarrays containing 184 GC tissues. Separate and combined features were evaluated for their impact on overall
survival (OS).
Results: We found that traditional factors including tumor size, histological grade, lymph node status, serosa
invasion and TNM stage were associated with OS (P < 0.05 for all). Moreover, statistically significant differences in OS
were found among lymph node ratio (LNR) subgroups (P < 0.001), MT1-MMP subgroups (P = 0.015), and CD11b +
immunocytes density subgroups (P = 0.031). Most importantly, combined feature (MT1-MMP positive, low CD11b +
immunocytes density and high LNR) was found by multivariate analysis to be an independent prognostic factors
for OS after excluding other confounding factors (HR = 3.818 [95%CI: 2.223-6.557], P < 0.001). In addition, this
combined feature had better performance in predicting clinical outcomes after surgery long before recurrence had
occurred (Area under the curve: 0.689 [95%CI: 0.609-0.768], P < 0.001).
Conclusions: These findings indicate that better information on GC prognosis could be obtained from combined
clinico-pathological factors, tumor cells and the tumor microenvironment.
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Gastric cancer (GC) is the fourth most common cancer
and the third cause of cancer death worldwide [1]. Consid-
erable progress has been made in the early diagnosis of
cancer, but there has not been a comparable advance in
the accuracy of clinical outcome prediction [2]. Only the
TNM classification of the International Union Against
Cancer (UICC) or American Joint Committee on Cancer
(AJCC) is used on a routine basis, which is the most* Correspondence: liyansd2@163.com
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reproduction in any medium, provided the orimportant instrument to guide treatment strategy for GC
patients [3]. However, GCs have significant heterogeneity
in their biologic behaviors, and tumors of the same clinical
stage often show differences in clinical course and treat-
ment response [4]. Thus, identification of factors affecting
invasion and metastasis, and establishment of biomarkers
panels to predict malignant potential and to identify differ-
ent risk groups are of a paramount importance.
Despite years of research and hundreds of reports on
tumor markers in GC, the number of clinically useful
markers is pitifully small [5]. Recently, a new prognostic
tool of lymph node ratio (LNR), defined as the number
of MLN divided by the number of lymph nodes re-
trieved, was proposed. It can improve the prognosis ac-
curacy and reduce the stage migration when comparedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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LNR has been considered as one of the best clinicopath-
ologic variables for prediction of prognosis of gastric
cancer after curative surgery in retrospective studies [8],
which is the success in the optimization of traditional
clinical markers. However, the discovery of other so-
called promising markers in laboratory translates rather
slowly into clinical applicability. One reason for this is
the fact that cancer development and progression is de-
termined by the co-evolution between tumor cells and
tumor microenvironment rather than a single mutation
[9]. Such co-evolution has been reported by many stud-
ies, all of which indicate that interactions between tumor
cells and tumor stromal create a unique and dynamic
microenvironment to affect tumor progression [10].
Therefore, screening new molecular factors from the
complex tumor microenvironment (cellular and stromal
components) represents another essential approach to
identify prognostic factors.
MT1-MMP is known as a membrane-type matrix
metalloproteinase, and MT1-MMP–mediated extracellu-
lar matrix (ECM) degradation by tumor cells or stromal
cells is essential for cancer invasion through basement
membranes and stromal interstitial matrix [11]. Although
MT1-MMP has shown prognostic significance in several
human cancers, such as breast cancer, pancreatic cancer
and colorectal cancer [12,13], little is known about the ac-
curate significance of MT1-MMP in GC patients. Major
contributors to the tumor microenvironment are inflam-
mation and inflammatory mediators [9]. It has been pro-
posed that the immune contexture may influence the
clinical outcome of the cancer patients, and the immune
score would be important predictor comparable to TNM
classification [14]. CD11b is expressed by a specific subset
of myeloid cells, including CD34+ progenitors, monocytes,
granulocytes, NK cells and activated T cells, accounting
for the innate immunity [15,16]. The role of tumor im-
munogenicity and immunotherapies are being discussed
[17]. Extending our knowledge of the complex role of im-
mune cells in GC could ultimately pave the way for the
long-awaited successful development of therapeutics.
Based on this understanding, we investigated prognostic
role of cellular proteinase marker MT1-MMP and micro-
environment immune marker CD11b + immunocytes in
GC. Special attention was paid to the prognostic value
of the combined features of MT1-MMP, CD11b +
immunocytes density and LNR.
Methods
Patients and follow-up
The records of GC patients who underwent surgery with a
curative intent at the Department of Oncology, Zhongnan
Hospital of Wuhan University (Wuhan, China) between
December 2002 and February 2011 were reviewed. Majordemographic and clinico-pathological characteristics were
available. No patients received neoadjuvant chemotherapy
before surgery. TNM stage was determined according to
the 7th edition UICC/AJCC TNM system [18]. By the
most recent follow-up on May 31, 2012, the median
follow-up was 59.5 (range: 16.8-102.3) months. A total of
108 (58.7%) patients died. Overall survival (OS) was de-
fined as the interval from the date of surgery to GC-
related death. Any recurrence in abdomino-pelvic cavity
was defined as local-regional recurrence; and recurrence
via blood flow was defined as distant metastasis, such as
liver metastasis and lung metastasis. Written informed
consent was obtained from the patients and the study
protocol was approved by the ethics committee of
Zhongnan Hospital of Wuhan University. The study was
undertaken according to the ethical standards of the
World Medical Association Declaration of Helsinki.
Gastric cancer specimens and tissue microarrays
All hematoxylin and eosin (HE)-stained slides were exam-
ined by independent reviewers who were not aware of the
clinical characteristics or clinical outcomes. Three tissue
microarrays (TMAs) were constructed. Briefly, two cores
were taken from each representative tumor tissue (1.5 mm
in diameter for each core). Then, three TMAs sections
with 184 tumor tissues were constructed (in collaboration
with Shanghai Biochip Company Ltd., Shanghai, China).
Immunohistochemistry and evaluation of
immunohistochemical findings
The primary antibodies for MT1-MMP (sc101451, Santa
Cruz, USA, dilution 1/100), CD11b + (ab52478, Abcam,
UK, dilution 1/100), the corresponding horseradish pero-
xidase (HRP) conjugated secondary antibody (ab97265,
ab97200, Abcam, UK, dilution 1/300), and diami-
nobenzidine (DAKO, Denmark) were obtained and vali-
dated for labeling.
The immunohistochemistry protocols were described
previously [19]. In short, three TMAs sections were
deparaffinised with xylene thenrehydrated through three
changes of alcohol. Endogenous peroxidase activity was
blocked by 0.3% hydrogen peroxide for 10 min. Antigen re-
trieval was performed by microwave treatment in 0.01 M
Tris-EDTA buffer (pH 9.0) for 20 min. Slides were incu-
bated for 1 h with the primary antibodies for MT1-MMP
(sc101451, Santa Cruz, USA, dilution 1/100), CD11b +
(ab52478, Abcam, UK, dilution 1/100). After washing with
Tris-buffered saline (TBS, pH 7.4), sections were incubated
with b the corresponding horseradish peroxidase (HRP)
conjugated secondary antibody (ab97265, ab97200, Abcam,
UK, dilution 1/300) for a further 50 min. Antigen–antibody
reaction was visualised with 3,30-diaminobenzidine
(DAKO, Denmark). After counterstaining with haematoxy-
lin, sections were dehydrated through ascending alcohols
Table 1 Patients’ demographics and clinico-pathological
characteristics
Items Value
Age (M ± SD, yrs) 57.9 ± 12.9
Gender
Male (%) 132 (71.7)
Female (%) 52 (28.3)
Tumor location
Distal stomach (%) 98 (53.3)
Non-distal stomach (%) 86 (46.7)
Pathological types
Adenocarcinoma











Others a (%) 5 (2.7)
Serosa invasion
No (T0, T1, T2) (%) 27 (14.7)
Yes (T3, T4) (%) 157 (85.3)
Lymph node metastasis
No (N0) (%) 53 (28.8)
Yes (N1, N2, N3) (%) 131 (71.2)
LNR, Median (Range) 0.33 (0-1)
Distant Metastasis
M0 (%) 177 (96.2)
M1 (%) 7 (3.8)
TNM stages
Early (Stages I, II) (%) 58 (31.5)
Advanced (Stages III, IV) (%) 126 (68.5)
Surgery
Subtotal resection (%) 159 (86.4)
Non-Subtotal resection (%) 25 (13.6)
Chemotherapy
No (%) 35 (19.0)
Yes (%) 149 (81.0)
Recurrence
No (%) 124 (67.4)




Table 1 Patients’ demographics and clinico-pathological
characteristics (Continued)
Clinical status at the end of the follow up
Live and without recurrence 72 (39.1)




CD11b + immunocytes (cells/mm2)
Median (range) 257 (4-2101)
a Others included adenosquamous carcinoma in 3 (1.62%) cases, untypical
carcinoid in 1 (0.54%) case, and neuroendocrine carcinoma in 1 (0.54%) case.
b 60 recurrent cases were evaluated.
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performed in parallel with paraffin sections of normal hu-
man tonsil. Negative control was performed by omitting
the primary antibody.
The slides were examined under Olympus BX51 fluores-
cence microscope equipped with an Olympus DP72 cam-
era (Olympus Optical Co., Ltd., Tokyo, Japan). Panorama
of each labeled core was obtained based on 4 photographs
under low-power magnification (×100) with high reso-
lution by DP-BSW software (Olympus Optical Co., Ltd.,
Tokyo, Japan). Identical settings were used for every
photograph, so as to minimize the selection bias. The
MT1-MMP expression and CD11b + immunocytes dens-
ity were digitally evaluated by Image-Pro Plus v6.2 soft-
ware (Media Cybernetics Inc, Bethesda, MD). To keep
results reliable and comparable, a uniform setting for all
the slides was applied for the reading of each antibody
staining. Integrated optical density (IOD) of all the positive
staining of MT1-MMP in each photograph was measured,
and its ratio to total area of each photograph was calcu-
lated as MT1-MMP expression. CD11b+ immunocytes
density was recorded as the number of positive cells per
tissue surface unit in square millimeters. Cut points for
MT1-MMP density was explored by “the best cut-off
approach by log-rank test” [20]. And the 25th percent-
ile value was defined as the cut-off point to determine
the MT1-MMP negative and positive expression sub-
groups in this study. For the CD11b + immunocytes
density, the cut-off point for the definition of subgroups
(low and high CD11b + immunocytes density) was the
median value.Statistical analysis
Statistical analyses were performed with SPSS software
(version 18.0, SPSS Institute, Chicago, IL). The Pearson χ2
test or Fisher’s exact test was used to compare qualitative
variables. Kaplan-Meier analysis was used for survival ana-
lysis and significance among patients’ subgroups was
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used to perform multivariate analysis. Logistic regression
was used to assess the influence of binary factors. Receiver
operating characteristic curve (ROC) analysis was used to
determine the predictive value of the parameters. Two
sided P < 0.05 was considered as statistically significant.
Results
Major clinico-pathological features and
immunohistochemical findings
Among the 184 cases included in this study were 132
(71.7%) males and 52 (28.3%) females, ranging in age from
25 to 85 yr (Mean ± SD: 57.9 ± 12.9 yr). The main de-
mographic and clinico-pathological characteristics were
presented in Table 1.
Immunohistochemistry was performed in all GC
TMAs and the result of each specimen was obtained for
images-based digital analysis (Figure 1A-1D). MT1-MMP
staining was mainly in the cytoplasm or on the cellFigure 1 Immunohistological findings in TMAs. (A-D) Representative ex
tissue microarray, and the corresponding digital image analyzed with the im
represented in red. (E,G) MT1-MMP staining was mainly in the cytoplasm o
stroma cells had negative staining, although sporadic positive staining on t
CD11b + immunocytes mainly infiltrated into the juncture of cancer nest anmembrane of tumor cells. Most of the stromal cells were
negative, although sporadic positive staining on these cells
was also observed (Figure 1E, 1G). CD11b + immunocytes
mainly infiltrated into the juncture of cancer nest and
stromal (Figure 1F, 1H). The level of MT1-MMP density
and CD11b + immunocytes density were presented in
Table 1. The 25th percentile of MT1-MMP density was
0.00186 and 138 (75.0%) patients were documented as
MT1-MMP positive according to the abovementioned
classification criteria. The median value of CD11b +
immunocytes were 257 cells per tissue surface unit in
square millimeter.
Relationship between MT1-MMP expression, CD11b +
immunocytes density and clinico-pathological features
There were 77 (55.8%) and 15 (32.6%) patients with high
CD11b + immunocytes density in MT1-MMP positive
(n = 138) and negative (n = 46) subgroups, respectively
(P = 0.006). The likelihood of MT1-MMP expression wasample of MT1-MMP (A), CD11b + immunocytes (C) staining of a GC
age software, with MT1-MMP (B) and CD11b + immunocytes (D)
r on the cell membrane of tumor cells (Blue arrow), and most of the
hese cells was also observed (F,H). CD11b staining showed that
d stroma, especially at the invasive front (Red and Green arrows).
Table 2 The relationship between MT1-MMP, CD11b + immunocytes density and cinico-pathological features
Variables
MT1-MMP expression CD11b + immunocytes density
Negative (n = 46) Positive (n = 138)
P
Low (n = 92) High (n = 92)
P
N (%) N (%) N (%) N (%)
Age (yrs)
<60 26 (56.5) 20 (43.5)
0.669
43 (43.4) 56 (56.6)
0.055
≥60 73 (52.9) 65 (47.1) 49 (57.6) 36 (42.4)
Gender
Male 33 (25.0) 99 (75.0)
1.000
66 (50.0) 66 (50.0)
1.000
Female 13 (25.0) 39 (75.0) 26 (50.0) 26 (50.0)
Tumor size (cm2) a
<16 12 (16.4) 61 (83.6)
0.007
35 (47.9) 38 (52.1)
0.404
≥16 31 (35.2) 57 (64.8) 48 (54.5) 40 (45.5)
Location
Distal 18 (18.4) 80 (81.6)
0.027
51 (52.0) 47 (48.0)
0.555
Non-distal 28 (32.6) 58 (67.4) 41 (47.7) 45 (52.3)
Histological grade b




3/4 31 (25.0) 93 (75.0) 63 (50.8) 61 (49.2)
Lymph node metastasis
Yes 31 (23.7) 100 (76.3)
0.511
73 (55.7) 58 (44.3)
0.015
No 15 (28.3) 38 (71.7) 19 (35.8) 34 (64.2)
LNR c
≤0.33 27 (28.7) 67 (71.3)
0.233
39 (41.5) 55 (58.5)
0.018
>0.33 19 (21.1) 71 (78.9) 53 (58.9) 37 (41.1)
Serosa invasion (T stage)
T1-2 4 (14.8) 23 (85.2)
0.186
10 (37.0) 17 (63.0)
0.145
T3-4 42 (26.8) 115 (73.2) 82 (52.2) 75 (47.8)
TNM staging
Early (I, II) 13 (22.4) 45 (77.6)
0.583
21 (36.2) 37 (63.8)
0.011
Advanced (III, IV) 33 (26.2) 93 (73.8) 71 (56.3) 55 (43.7)
Recurrence
Yes 9 (15.0) 51 (85.0)
0.029
30 (50.0) 30 (50.0)
1.000
No 37 (29.8) 87 (70.2) 62 (50.0) 62 (50.0)
Recurrence location d
Local-regional 7 (18.9) 30 (81.1)
0.460
20 (54.1) 17 (45.9)
0.426
Distant 2 (8.7) 21 (91.3) 10 (43.5) 13 (56.5)
a Analysis was performed based on 161 patients with complete data of tumor size (TS).b Analysis was performed based on 179 patients with gastric
adenocarcinoma.c The median of lymph node ratio (LNR) was 0.33 (6 cases), and GC cases were different in distinct subgroups. d 60 recurrent cases
were included.
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density subgroup (odds ratio (OR) = 0.383 [95%CI:
0.190-0.774], P = 0.007, Logistic regression). The MT1-
MMP expression and CD11b + immunocytes density
were correlated with the clinico-pathological features
as summarized in Table 2. MT1-MMP expression was
correlated with small tumor size (P = 0.007), tumor at
distal stomach (P = 0.027) and increased recurrencerisk (P = 0.001), but not correlated with age, gender,
histological grade, serosa invasion, lymph node status,
TNM stage and sites of tumor recurrence (P > 0.05 for
all). CD11b + immunocytes density was correlated with
lymph node status (P = 0.015), LNR (P = 0.018) and
TNM stage (P = 0.011), but not correlated with age,
gender, tumor size, tumor location, histological grade,
serosa invasion and recurrence risk (P > 0.05 for all).
Figure 2 Cumulative OS of GC patients. (A) OS of 184 GC patients. (B) Low CD11b + immunocytes density was related to poor OS. (C) Patients
in MT1-MMP positive group were at higher risk for death. (D, E) Both lymph nodes status and LNR were correlated with poor OS, but LNR could
better differentiate patient subgroups. (F) Combined Features could indicate OS of GC patients more accurately.
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For 184 cases, the median OS was 26.8 (range 0.8-
102.3) months, and the 1-, 3-, and 5-yr survival rate was
79.3%, 50.5% and 37.4%, respectively (Figure 2A).
As expected, those traditional factors were associated
with GC patients’ OS, such as tumor size, histological
grade, lymph node status, serosa invasion and TNM
stage (P < 0.05 for all). In addition, both high CD11b +
immunocytes density and MT1-MMP negative expres-
sion were correlated with better OS (P value was 0.031 and
0.015, respectively.) (Figure 2B, 2C). The discriminationability in OS was increased in LNR subgroups (P < 0.001)
compared to lymph nodes status subgroups (P = 0.015)
(Figure 2D, 2E ), and ROC analysis showed that, in terms
of predicting risk of death, the classification by LNR
(Area under the curve: 0.659 [95%CI: 0.579-0.739], P <
0.001) had better performance than positive lymph nodes
number (Areas under the curve: 0.568 [95%CI: 0.484-
0.653], P = 0.114). All results indicated that MT1-MMP
positive, low CD11b + immunocytes density and high LNR
were risk factors related to poor prognosis (Figure 2,
Table 3).
Table 3 Analyses of factors regarding OS
Variables N N of death (%) Median OS (Range) 5-year survival rate (%) Log-rank test χ2 value P
Age (yrs)
<60 99 52 (52.5) 30.1 (1.5-99.5) 45.1 3.584 0.058
≥60 85 56 (65.9) 24.8 (0.8-102.3) 28.6
Gender
Male 132 74 (56.1) 30.3 (0.8-102.3) 40.0 2.114 0.146
Female 52 34 (65.4) 25.1 (1.3-94.8) 30.3
Tumor size (cm2) a
<16 73 35 (47.9) 41.6 (1.1-99.5) 52.9 7.882 0.005
≥16 88 57 (64.8) 24.2 (0.8-102.3) 29.2
Histological grade b
1/2 55 88 (56.1) 30.1 (1.1-102.3) 54.2 13.412 <0.001
3/4 124 20 (74.1) 16.8 (0.8-74.9) 30.1
Lymph nodes metastasis
Yes 131 83 (63.4) 24.8 (0.8-102.3) 52.9 5.895 0.015
No 53 25 (47.2) 34.1 (6.1-99.5) 30.5
Serosa invasion (T stage)
T1-2 27 7 (25.9) 58.9 (20.2-99.5) 74.9 14.742 <0.001
T3-4 157 101 (64.3) 24.8 (0.8-102.3) 30.8
TNM
Early (I, II) 58 26 (44.8) 35.8 (6.1-99.5) 54.0 9.823 0.002
Advanced 126 82 (65.1) 22.8 (0.8-102.3) 29.2
(III, IV)
Surgery
SR 159 89 (56.0) 30.0 (0.8-102.3) 39.8 5.902 0.015
TR/CR 25 19 (76.0) 18.0 (3.8-89.9) 21.8
Chemotherapy
Yes 149 87 (49.7) 33.5 (5.3-99.5) 35.9 0.016 0.900
No 35 21 (60.0) 28.4 (0.8-102.3) 40.0
LNR c
≤0.33 94 41 (43.6) 38.8 (1.1-102.3) 55.1 24.881 <0.001
>0.33 90 67 (74.4) 20.1 (0.8-99.1) 18.3
MT1-MMP
Negative 46 18 (39.1) 35.7 (3.8-79.3) 54.0 5.869 0.015
Positive 138 90 (65.2) 25.4 (0.8-102.3) 32.2
CD11b + immunocytes density
Low 92 62 (67.4) 25.1 (0.8-99.1) 27.6 4.655 0.031
High 92 46 (50.0) 30.7 (1.3-102.3) 46.7
Combined features (MT1-MMP density, CD11b + immunocytes density and LNR)
Group I 73 26 (35.6) 38.7 (6.1-94.1) 61.4 28.173
<0.001Group II 111 82 (73.9) 18.1 (0.8-90.9) 21.1
a Analysis was performed based on 161 patients with complete data of tumor size. b Analysis was performed based on 179 patients with gastric adenocarcinoma.
c The median of LNR was 0.33 (6 cases), and GC cases were different in distinct subgroups.OS: overall survival; SR: subtotal resection; TR: total resection; CR:
combined resection; LNR: lymph node ratio.
Peng et al. Journal of Translational Medicine 2013, 11:153 Page 7 of 11
http://www.translational-medicine.com/content/11/1/153




HR 95% CI P
Model 1
Tumor size: <16 cm2 vs ≥16 cm2 1.821 1.168-2.839 0.008
Serosa invasion (T stage): T1-2 vs T3-4 3.232 1.440-7.251 0.004
Lymoh nodes metastasis: No vs Yes 1.012 0.610-1.679 0.964
Surgery types: SR vs TR/CR 2.030 1.128-3.653 0.018
LNR: low (≤0.33) vs High (>0.33) 1.957 1.233-3.108 0.004
MT1-MMP: Negative vs Positive 2.596 1.496-4.506 0.001
CD11b + immunocytes density: High vs Low 1.838 1.183-2.855 0.007
Model 2
Tumor size: <16 cm2 vs ≥16 cm2 1.734 1.120 - 2.686 0.014
Serosa invasion (T stage): T1-2 vs T3-4 3.013 1.360 - 6.674 0.007
Lymoh nodes metastasis: No vs Yes 0.696 0.404 - 1.200 0.192
Surgery types: SR vs TR/CR 2.023 1.134 - 3.606 0.017
Combined features: Group I vs Group II 3.818 2.223 - 6.557 <0.001
OS: overall survival; HR: hazard ratio; NA: not adopted; SR: subtotal resection;
TR: total resection; CR: combined resection; LNR: lymph node ratio.
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the number of risk factors were explored to improve
prediction of GC prognosis (Table 3). Thus, patients
were divided into two subgroups according to the num-
ber of risk features: group I, less than two risk factorsFigure 3 ROC analysis of the predictive value for death. Among the 4
combined feature was the largest one. The combined feature could have bwere observed; and group II, two or three risk factors
were observed. Combined analysis showed that the OS
of patients in group II was significantly shorter than
patients in group I (P < 0.001) (Figure 2F).
Multivariate analysis and ROC analysis
In univariate analysis, traditional clinico-pathological fea-
tures (such as tumor size, T stage, TNM stage, surgery
methods, and recurrence status), MT1-MMP expression,
CD11b + immunocytes density and LNR were associated
with OS. Furthermore, the death risk in combined group
II increased significantly (P < 0.001).
Factors showing significance by univariate analysis were
integrated into multivariate Cox proportional hazards ana-
lysis. In this study, LNR, MT1-MMP, CD11b and com-
bined features were highly correlated. Therefore, two
separate multivariate models were generated to avoid the
multicollinearity among those variables. LNR, MT1-MMP
expression and CD11b + immunocytes density were inde-
pendent prognostic factors for OS after excluding other
confounding factors (P < 0.05 for all) Moreover, the com-
bined features were independent prognostic factor, too
(HR = 3.818 [95%CI: 2.223-6.557], P < 0.001) (Table 4).
ROC analysis was implemented to further evaluate the
prognostic performance of the four independent factors
in this study. Combined features would be better to pre-
dict the clinical outcomes of GC patients compared to
other factors (Area under the curve: 0.689 [95%CI:
0.609-0.768], P < 0.001) (Figure 3).independent prognostic factors, the area under the curve of the new
etter prognostic performance in GC patients.
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We have proposed a combined analysis of integrated
tumor stromal features as a useful strategy to evaluate
cancer progression and patient survival in GC based on
our studies focused on the co-evolution of tumor cells
and tumor microenvironment and [19,21,22]. This study
was designed to explore the feasibility of this combined
strategy. In addition, an improved automation method
to analyze the digitalized images was used to ensure
both reproducibility and good performance in this study.
As Fridman [23] suggested, such methods would pave
the way to better understanding the complex tumor
microenvironment, as well as to the routine evaluation
of parameters for clinical management of cancer pa-
tients. Herein, 184 GC cases were included to evaluate
the prognostic values of optimized conventional patho-
logical prognostic factors, cellular molecular factors, im-
mune factors and the combined features. This is the
essential step towards establishing a workable prognostic
system integrating both clinico-pathological, tumor and
stromal features in our series studies [19,21,22].
Of 184 cases, the demographics and clinico-pathological
characteristics are similar to those reported in other large
series of GC population [24]. Our results showed that the
expression of MT1-MMP was frequently correlated with
increased recurrence risk, but the difference in relapse loca-
tion was not statistically significant. These results were
similar to previous report [25]. MT1-MMP plays important
role in degrading types I and IV collagens to facilitate can-
cer cells spreading. In addition, MT1-MMP can promote
angiogenesis and micrometastasis via vascular route [26].
With regard to immune cells, the nature, density and
location are important parameters to comprehensively
evaluate the in situ immune reaction and the specific
role in cancer progression. In this study, CD11b +
immunocytes were mostly located at the invasive front.
The difference in CD11b + immunocytes density was sta-
tistically significant between lymph nodes metastasis and
non-metastais subgroups. Furthermore, the CD11b +
immunocytes density was higher in early than advanced
GC patients, similar to the reports by Sconocchia et al.
and Ladoire et al. [27,28]. Hence, we hypothesized that
CD11b + immunocytes could prevent the lymph nodes
metastasis by active immunosurveillance process.
The prognostic value of traditional clinicopathological
prognostic factors has been validated [29,30]. Interest-
ingly, some studies reported that the LNR was a better
predictor of patient outcome than lymph nodes status
only. LNR may be an alternative stratification in cases
where few nodes are retrieved [3,8]. LNR has also been
adopted by the Japanese Gastric Cancer Association
(JGCA) [31].
Researches focused on molecular factors for cancer
progrosis have attracted increasing attention [32,33]. In thisstudy, MT1-MMP expression and CD11b + immunocytes
density were independent prognostic factors, which partly
validated others’ conclusions about MT1-MMP and
CD11b + immunocytes. Kanazawa et al. [34] reported that
MT1-MMP expression could be considered as a useful in-
dependent predictor of outcomes in colorectal cancer pa-
tients. The results presented by Mahmoud et al. [35]
confirmed the presence of efficient immunologic antitumor
defense mechanisms in human breast cancer. It is pro-
posed that immune score would identify a population of
patients who would derive substantial benefit from further
stimulating their immune response [36]. Several studies
have also provided evidence of immune criteria to predict
which tumors have a high risk of death [35,37].
Given the fact that tumor biology is often dictated by
several essential cellular and microenvironmental alter-
ations, it may be naive to think that single factor would
be enough as prognostic factors in cancer [38]. Solutions
are now being explored by analyzing multiple factors
with tissue microarrays, which has been emerged as an
essential tool in the discovery and validation of tissue
biomarkers [39]. To our knowledge, combined analysis
is a promising method to translate experimental results
into clinical application [40]. Based on our results and
current knowledge in cancer progression, we proposed a
new prognostic model that combines pathological, cellu-
lar and molecular features. This study showed that the
combined features were independent prognostic factors
for OS. The death risk of GC patients in group II was
increased by 200% and this combined features would
better predict GC patients’ outcomes.
The development of tumor biomarkers ready for clin-
ical use is complex, and a useful prognostic marker
must be a proven independent, significant factor, that is
easy to determine and interpret and has therapeutic im-
pact [41]. Although the combined features described
herein could address these conditions, the promising re-
sults are based on retrospective analysis, which is the
limitation of this study. Prospective randomized clinical
trials to evaluate the clinical utility of a prognostic or pre-
dictive biomarker are the gold standard, but such trials are
costly and difficult to implement, and more efficient indir-
ect “retrospective analysis” using archived specimens
would be an alternative method for a long time [42].Conclusions
Our study provides evidence for the value of the com-
bined features to predict OS in GC patients. The com-
bined features of positive MT1-MMP, low CD11b +
immunocytes density and high LNR may be used as use-
ful prognostic factor in clinical circumstance in future.
Further studies with larger sample size could help gain
deeper insights into the role of combined features.
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